N⁶-Methyladenosine in Cancer Immunotherapy: An Undervalued Therapeutic Target

Chao Quan††, Othmane Belaydi††, Jiao Hu†, Huihuan Li†, Anze Yu†, Peihua Liu†, Zhenglin Yi†, Dongxu Qiu†, Wenbiao Ren†, Hongzhi Ma‡, Guanghui Gong§, Zhenyu Ou†, Minfeng Chen†, Yin Sun§, Jinbo Chen†* and Xiongbing Zu†*

†Department of Urology, Xiangya Hospital, Central South University, Changsha, China, ‡Center for Inflammation and Epigenetics, Houston Methodist Research Institute, Houston, TX, United States, §George Whipple Lab for Cancer Research, University of Rochester Medical Center, Rochester, NY, United States, ¶Department of Radiation Oncology, Hunan Cancer Hospital, Central South University, Changsha, China, ¶Department of Pathology, Xiangya Hospital, Central South University, Changsha, China

N⁶-methylation of adenosine (m⁶A), a post-transcriptional regulatory mechanism, is the most abundant nucleotide modification in almost all types of RNAs. The biological function of m⁶A in regulating the expression of oncogenes or tumor suppressor genes has been widely investigated in various cancers. However, recent studies have addressed a new role of m⁶A modification in the anti-tumor immune response. By modulating the fate of targeted RNA, m⁶A affects tumor-associated immune cell activation and infiltration in the tumor microenvironment (TME). In addition, m⁶A-targeting is found to affect the efficacy of classical immunotherapy, which makes m⁶A a potential target for immunotherapy. Although m⁶A modification together with its regulators may play the exact opposite role in different tumor types, targeting m⁶A regulators has been shown to have wide implications in several cancers. In this review, we discussed the link between m⁶A modification and tumor with an emphasis on the importance of m⁶A in anti-tumor immune response and immunotherapy.

Keywords: N⁶-methyladenosine, m⁶A, tumor microenvironment, immune response, immunotherapy

BACKGROUND

The expression of genetic information is regulated at multiple levels. RNA modification, a post-transcriptional regulatory mechanism, is thought to alter the RNA function through changing the chemical-structural features of RNA (1). One hundred and seventy-two kinds of RNA modifications have been reported, most of which are restricted to non-coding RNA (ncRNA) instead of messenger RNA (mRNA) (2, 3). Unlike most other RNA modifications, m⁶A, which is first identified in the 1970s (4, 5), is an abundant nucleotide modification in almost all types of RNAs, including mRNA and ncRNA, and is involved in various physiological and pathological processes (6). Generally, the rise in m⁶A methylation in cancer cells plays a tumor-suppressor role with only a couple of studies showing the opposite (7–9). By targeting specific RNA, m⁶A triggers certain alterations to tumor-specific mRNA/ncRNA behavior and biologic activity, thereby influencing tumor progression.
Compared with the conventional therapies (radiation and chemotherapy) for cancers that directly target tumor cells, anti-tumor immunotherapy, which promotes a systemic immune response against tumors, exhibits great potential in cancer treatment (10). m^6^A, whose intrinsic function in tumor cells has been widely studied and discussed, is proved to influence the anti-tumor immune response and can be a novel target in anti-tumor immunotherapy (11–14). In this review, we briefly introduce the regulation and function of m^6^A, with an emphasis on the role of m^6^A in anti-tumor immune response and a summary of prominent m^6^A-related functions and strategies in immunotherapy.

THE REGULATION AND FUNCTION OF M^6^A MODIFICATION

The m^6^A modification, a dynamic and reversible methyl-modification occurring at the N^6^ position of adenine (A) bases in RNA, is enriched in the internal exons, 3' untranslated region (3'UTR) and the stop codon and restricted to a consensus sequence DRACH (D=G, A, or U; R=G or A; H=A, C, or U) (15–17). Generally, the regulation and function of m^6^A modification involve three kinds of protein factors: methyltransferases (writers), binding proteins (readers), and demethylases (erasers).

Writers

'Writers' mediate m^6^A modifications by adding methylation to RNA. The classic 'writer complex' includes a core heterodimer consisted of methyltransferase-like 3 (METTL3) and methyltransferase-like 14 (METTL14), together with several accessory proteins (Wilms tumor 1-associated protein (WTAP), zinc finger CCCH domain-containing protein 13 (ZC3H13), RNA binding motif protein 15 (RBM15) or RBM15B and Vir like m^6^A methyltransferase associated (VIRMA) (11). METTL3 is responsible for catalyzing methyl-translocation from methyl donor [S-adenosylmethionine (SAM)] to RNA, while METTL14 mediates m^6^A deposition through recognizing and binding to the target RNA (18, 19). As a regulatory subunit, WTAP interacts with the METTL3/14 heterodimer and mediates the localization of the heterodimer in nuclear speckles (20). ZC3H13, RBM15 or RBM15B, and VIRMA are all WTAP-related and facilitate the nuclear localization and specificity of the 'writer complex' (21–23). In addition to the classic 'writer complex', several other enzymes independently catalyze the methyl transfer to target RNA, including METTL16 targeting U6 small nuclear RNAs, zinc finger CCHC-type containing 4 (ZCCHC4) targeting ribosomal RNAs, METTL5 targeting 18S ribosomal RNAs and PDX1 C-terminal inhibiting factor 1 (PCIF1) targeting 7-methyl guanosine (m7G)-capped mRNAs (11).

Readers

'Readers' bind to m^6^A on modified RNAs and induce various biological effects (24). YT521-B homology (YTH) domain-containing 'readers', which bind RNA in an m^6^A-dependent manner, are categorized into three types: YTHDC1, YTHDC2 and YTHDF family proteins (YTHDFs) (11). YTHDC1 mainly affects mRNA splicing within the nucleus and participates in the nuclear export of mRNA (25, 26), whereas YTHDC2 promotes the translation as well as degradation of the targeted mRNA in/ out the nucleus (27–29). There are three members in the YTHDF family: YTHDF 1, 2 and 3. However, their functions remain unclear, and further studies are needed (30). Some other RNA-binding proteins which preferentially bind to m^6^A-containing RNA are thought to be 'readers' too (11). However, more studies are also needed to decipher their regulatory functions and determine whether their preference for m^6^A-containing RNA is due to specific recognition for m^6^A (31).

Erasers

'Erasers' are responsible for removing m^6^A from mRNA. The fat-mass and obesity-associated protein (FTO) and Alpha-ketoglutarate-dependent dioxygenase ALK B homologue 5 (ALKBH5) are two demethylases that proved to remove methylation on adenosine from RNA (17, 32, 33). FTO removes both m^6^A and N^6^,2'-O-dimethyladenosine (m^6^Am^6^A), whereas ALKBH5 specifically demethylates m^6^A (17, 32). Though FTO and ALKBH5 both are 'erasers', their biological function can be quite different. They act as either an oncogene or a tumor suppressor depending on tumor types (6, 34). It is clear that the different biological effect of 'erasers' is the result of demethylation of specific target mRNAs, but what leads to the mRNA selectivity still need to be addressed.

Regulatory Function of m^6^A

The regulatory function of m^6^A on mRNA and ncRNA is very critical in a lot of key biological processes (Figure 1).

m^6^A is deposited on mRNA under the mediation of writers and then enrolls in the whole lifecycle of mRNA. Mediated by the readers, m^6^A affects mRNA splicing and export within the nucleus and influences the stability, translation and localization of mRNAs in the cytoplasm. It has been proved that m^6^A on precursor mRNAs (pre-mRNAs) promotes the mRNA splicing by directly recruiting splicing factor or indirectly altering mRNA structure and subsequently increasing the accessibility of flanking RNA sequence to splicing factors (35–38). Moreover, the m^6^A writers, readers, and erasers are all associated with mRNA splicing (17, 20, 25, 33, 39). The m^6^A modification also promotes mRNA export from the nucleus to the cytoplasm, which is mediated by writers or readers (40, 41). Although m^6^A modification is suggested to accelerate and promote the mRNA translation through several mechanisms, it still shows a negative correlation with mRNA half-life (42–44). This indicates that m^6^A may enhance mRNA translation by depending more on its readers rather than lengthening mRNA lifetime. A closed-loop model, in which eukaryotic translation initiation factor 3 (eIFs) subunit at the 5' end of the mRNA interacts with METTL3 or YTHDF1 that is bound to m^6^A sites near the stop codon, is proposed to explain how m^6^A regulates mRNA translation (45, 46). YTHDFs, which specifically recognize m^6^A, are shown to regulate mRNA translation and degradation. YTHDF1 recruits
eukaryotic translation initiation factor 3 (eIF-3) complex, which leads to enhanced mRNA translation (45), while YTHDF2 mediates the degradation of mRNA through recruiting Ccr4-Not deadenylase complex (42, 47). YTHDF3 function is variable, which is linked with either mRNA translation promotion or degradation acceleration (48, 49). However, the insulin-like growth factor-2 mRNA-binding protein (IGF2BP) enhances the mRNA stability by recognizing m6A and facilitate mRNA translation (50–52). METTL3 promotes mRNA translation through directly recruiting eIF3 in the cytoplasm (46, 53). In addition, translational enhancement of m6A is partially mediated by the direct binding of eIF3 to m6A in the 5′UTR (54).

In addition to mRNA, m6A and its regulators has also been found to affect the biological activity of other ncRNAs (55). METTL3-mediated m6A methylation on primary microRNA (pri-miRNA) are proved to promote the microRNA (miRNA) maturation in various pathophysiological processes (35, 56, 57). Mechanically, METTL3 methylates pri-miRNAs marking them for recognition and processing by DGCR8, which is the first step in the biogenesis of miRNAs (58). METTL3 may also promote the synthesis of mature miRNAs by increasing the splicing of pre-miRNAs by Dicer (59). For long ncRNA (lncRNA), METTL3-mediated m6A modification on lung cancer associated transcript 3 (LCAT3), a long ncRNA (lncRNA), leads to the lncRNA stabilization (60), while METTL14-mediated m6A modification on lncRNA XIST facilitates the degradation of XIST which is attributable to YTHDF2 (61). In addition, m6A modification on circRNA has been identified and characterized (62). Furthermore, m6A modifications are believed to be involved in the biogenesis, translation, export and endoribonucleolytic cleavage of circRNAs, which has been discussed (63).

**ROLE OF M6A IN ANTI-TUMOR IMMUNE RESPONSE**

The role of intrinsic m6A modifications in modulating tumor fate through regulating specific target genes in different cancers has been thoroughly discussed (6, 62, 64). However, the link between aberrant m6A modifications and the anti-tumor immune response has received less attention, which has been indicated to be a potential therapeutic target in anti-tumor immunotherapy (Figure 2) (13, 65, 66).

**Role of m6A in TME Immune Response**

The TME plays an important role in cancer progression and is also largely responsible for immunotherapeutic responsiveness. This is highlighted in tumor with T-cell-inflamed TME, containing abundant infiltration of CD8+ T cells (67), and thus predicting a better clinical outcome due to priming for the efficacy of immunotherapy (68), unlike the non-T-cell-inflamed TME. Interestingly, bioinformatical analysis shows that m6A modifications and its regulators are associated with the TME response and immune checkpoint blockade (ICB) efficacy in several tumor types. Moreover, it has been found that m6A modification influence the infiltration, activation and function of immune cell in TME, which makes m6A-targeting a promising therapy (65, 69).

m6A Is Associated With TME and Immunotherapy Efficacy

Many studies have confirmed the association between m6A modifications and TME condition in cancers with different histogenesis and organ location.
In renal clear-cell carcinoma (RCC), low m^6^A score group was characterized by a hot/inflammatory TME, which may be more sensitive to anti-tumor immunotherapy (70). Similar result was found in a RCC cohort that m^6^A score was negatively correlated with antigen processing machinery (APM) (71). Moreover, low m^6^A score, characterized by increased mutation burden and activation of immunity, indicates an inflamed TME phenotype and enhanced response to anti-PD-1/L1 immunotherapy in gastric cancer (GC) (65). In addition, m^6^A-related signature has been identified as biomarker for tumor immune phenotypes and anti-PD-1 immunotherapy treatment response in lung adenocarcinoma (LADC) (72, 73), stomach adenocarcinomas (STADs) (74), Esophageal squamous cell carcinoma (ESCC) (75, 76), Renal Papillary Cell Carcinoma (RPCC), Hepatocellular Carcinoma (HCC) (77, 78). These statistical results together indicate that m^6^A modification may reflect TME status and predict immunotherapy efficacy in pan-cancers instead of limited to specific cancer types. However, heterogeneity between these analysis limits the application in clinical practice, since each study focused on single cancer type and included different m^6^A indicator for analysis.

### Remolding TME by Targeting m^6^A Regulator

Considering the potential effect of m^6^A on TME, it is promising to remolding TME through enhancing or reducing m^6^A modification by targeting m^6^A regulator.

METTL14, along with METTL3, affects the number of CD8+ T cells infiltrating into tumors since its depletion led to an increase of CD8+ T cells, in addition to as well as IFN-γ, CXCL9 and CXCL10 in colorectal cancer (CRC) (13). Moreover, depletion of Mettl3 and Mettl14 enhanced the response to anti-PD-1 treatment in pMMR-MSI-L CRC and melanoma (13).

FTO, prompted by metabolic stress and starvation through the NF-kB signaling pathway and autophagy, increases melanoma growth and decreases response to anti-PD-1 blockade immunotherapy by protecting tumor cell-intrinsic genes (PD-1 (PDCD1), CXCR4 and SOX10) mRNA from decaying. In addition, in the case of endometrial cancer, FTO is also found to be changing the TME through regulating matrix metalloproteinase (MMPs), which are key player enzymes in promoting cancer growth (79, 80). Moreover, FTO can also directly upregulate leukocyte Ig-like receptor B4 (LILRB4) which is an immune checkpoint gene expression via an m^6^A-dependent mechanism in AML. CS1/CS2 (FTO inhibitor) treatment decreased the expression of LILRB4 in AML cells and substantially increased the sensitivity of AML cells to the cytotoxicity of activated T cells (81).

ALKBH5 alteration in tumor cell modulating its lactate content affects the tumor infiltration of Tregs and myeloid-derived suppressor cells (MDSCs) in TME, which are notorious immunosuppressants in anti-tumor immunity.
ALKBH5 also regulates Mct4/Slc16a3 expression and DCs abundance. These regulations were highlighted when knocking down ALKBH5 along with administering GVAX/anti-PD-1 treatment resulted in Tregs and MDSCs infiltration of tumors to go down, DCs to increase and Mct4/Slc16a3 expression and lactate content in TME to decrease. ALKBH5, unlike FTO, is not changing the TME by affecting the IFN-γ pathway since the population of CD8+ T lymphocytes remains unchanged when the demethylase is depleted (82). In addition, single-cell mass cytometry analysis unveiled a role of ALKBH5 in TME by promoting the expression of PD-L1 on monocytes/macrophages and decreasing the infiltration of MDSCs (83).

In addition, Wnt/β-catenin pathway has been linked to m6A modifications and cancer in many studies. For example, Wnt/β-catenin signaling, which is, at least partially, overexpressed due to frizzled class receptor (FZD) 10's m6A modification, contributes to epithelial ovarian cancers (EOC) resistance to poly ADP-ribose polymerase inhibitor (PARPi) (84). Wnt/β-catenin hyperactivation through FZD7 overexpression, a Wnt receptor, which has its elevation mediated by YTHDF1, leads to GC carcinogenesis (85) and Wnt pathway activation by FTO promotes endometrial cancer (86). Activation of the Wnt/β-catenin pathway is considered as a potential cause in developing the non-T cell inflamed TME since it is usually associated with poor T cell infiltration (a lack of CD8+ T cells along with DCs) among most human cancers. This activation also renders the tumors resistant to immune checkpoint therapy, in addition to resistance to vaccination and adoptive T cell transfer in the case of β-catenin-expressing melanomas. Therefore, targeting the Wnt/β-catenin pathway is a high priority for reversing non-T cell inflamed TME and sensitizing patients to different types of therapy (68).

**m6A in Immune Cell**

As an important part of anti-tumor response, tumor infiltrating lymphocytes (TILs) and other immune cells is vital for shaping the TME and anti-tumor immunotherapy. While few published research on the effect of m6A on immune cell function is available (Figure 3).

METTL3-mediated m6A modification is found to be promoting DCs activation and maturation, leading to the induction of T cell activation. This promotion is through METTL3 enhancement of the translation efficiency of CD40, CD80 and TIR domain containing adaptor protein (TIRAP; a crucial TLR4/NF-κB signaling pathway adaptor, which induces proinflammatory cytokines secretion) (87). METTL3 depletion in macrophages contributed to the formation of an immunosuppressive microenvironment with increased Treg infiltration and reduced Th1 cells and IFN-γ+CD8+ cells, and subsequently facilitated tumor growth and metastasis (88).

**FIGURE 3** | The schematic of m6A in immune cell. (1) In dendritic cells (DCs), YTHDF1 suppresses the antigen-presentation by DCs through maintain the expression of lysosomal cathepsins; METTL3-mediated m6A modification promotes DCs activation through enhancing the translation efficiency of CD40, CD80 and TIRAP. (2) METTL3 in Tregs sustains the suppression roles of regulatory T cells through IL-2-STAT5 signaling impairing CD8+ T cells tumor killing ability. (3) In macrophages, METTL3 sustains the YTHDF1-mediated translation of SPRED2, which inhibits NF-κB and STAT3 through the ERK pathway, restricting tumor growth and metastasis; METTL14-deficiency in macrophage impairs CD8+ T cells to eliminate tumors.
Moreover, METTL3-deficiency in macrophages impairs the YTHDF1-mediated translation of SPRED2, which enhances the activation of NF-kB and STAT3 through the ERK pathway, leading to increased tumor growth and metastasis (88). However, METTL3 also impairs CD8+ T cells tumor killing ability through sustaining the suppression roles of regulatory T cells (Tregs) (89). Depletion of Mettl3 in Tregs suppresses the IL-2-STAT5 signaling pathway which is essential to Treg functions and stability (89). Thus, METTL3 in Tregs may suppress the anti-tumor immune response by maintaining the immunosuppressive function of Tregs. METTL14-mediated m6A modification in tumor-associated macrophages (TAMs) were found to modulate tumor-infiltrating CD8+ T cells, since macrophage-specific knockout of Mettl14 drives CD8+ T cell differentiation along a dysfunctional trajectory, impairing CD8+ T cells to eliminate tumors (90).

YTHDF1 in DCs influences the anti-tumor immune response through impairing DCs’ lysosomal cathepsins. In summary, inhibition of YTHDF1 makes DCs more efficient at antigen presentation and, at the same time, improves CD8+ T cross-priming; thus, giving them more ability to repress tumors than the non-lacking YTHDF1 cells (12). Moreover, YTHDF1 inhibition also increases PD-L1 checkpoint blockade potency in cancer regression (12).

To date, role of m6A modification in immune cells was given little attention and most studies was conducted in tumor model, with a few exceptions focus on other pathophysiological process, including autoimmune disease (91), T cell homeostasis and differentiation (92) and macrophage polarization (93). In addition, single regulator may play the opposite role on immune response according to cell type, like METTL3 in DCs and Treg. Due to the inadequate data and confusing result, it’s hard to develop a strategy to promote anti-tumor immunity by targeting m6A in immune cell for now.

As discussed above, m6A modifications and its regulators affect tumor-associated immune cell activation and infiltration in TME. However, only a few m6A regulators has been investigated in several tumor or cell types. Moreover, m6A and its regulators play quite different role in the anti-tumor immune response according to tumor or cell type. Thus, more researches need to be done to identify the effect of aberrant m6A modification and exact biological function of each m6A regulators in different cancers or cell type context, especially in immune cells. In addition, m6A-targeting is found to affect the efficacy of classical immunotherapy preclinically, which further indicates the potential therapeutic value of m6A-targeting in tumor treatment.

**M6A IMPLICATION OF M6A MODIFICATIONS FOR CANCER IMMUNOTHERAPY**

Although m6A modification together with its regulators may play the exact opposite role in different types of tumors, targeting m6A regulators has been shown to have wide implications in several cancers. Since there is no clinical research investigating the efficacy of m6A-targeting strategy, we propose several pathways we might utilize to implement m6A area of research in the clinical settings of treatment, which is usually done by trying to selectively identify and then to inhibit the enzymes responsible for tumor exacerbation in specific cancers (Table 1).

**Targeting m6A Writers**

METTL3 and METTL14, as discussed earlier, play an oncogenic role and specifically targeting them can lead to better clinical outcomes. Examples of this include: (1) Depletion of the methyltransferases METTL3 in Tregs which enhances the anti-tumor ability of CD8+ T cells can be used as a strategy alongside immunotherapy for effective treatment (89). (2) Suppressing METTL3 and METTL14 increases CD8+ tumor-infiltrating lymphocytes in addition to the upregulation of IFN-γ, CXCL9, and CXCL10. Although this inhibition alone does not repress tumor growth, it is able to synergize with the immune checkpoint inhibitors such as anti-PD-1 therapy in both CRC and melanoma (13). Unfortunately, selective METTL3/METTL14 inhibitors for cancer therapies are not yet available, but bisubstrate inhibitors

| Table 1 | Potential strategies for m6A-targeting therapy. |
|----------|-----------------------------------------------|
| Target   | Name | Effect    | Cell type | Tumor         | Ref   |
| FTO      | FG-2216/IOX3 | I | T | melanoma | (94) |
|          | FG-4592/SelleckBio | I | T | (95) |
|          | Meflofenamic acid (MA) | I | T | (96) |
|          | Fluoresein | I | T | (97) |
|          | N-CDPCB | I | T | (98) |
|          | CHTB | I | T | (99) |
|          | FB23-2 | I | T | (100) |
|          | CS1/CS2 | I | T | (101) |
| ALKBH5   | Alk-04 | I | T | BC, GBM, LAC, CRC | (102) |
|          | MV1035 | I | T | (103) |
| METTL3-METTL14 | small-molecule ligand | A | T | CRC, melanoma | (89, 103) |
|          | bisubstrate inhibitor | I | T | (12) |
| YTHDF1   | small molecule, DC vaccine | I | DC | GC, OC, CRC, HCC | (104) |
| R-2HG    | IDH inhibitor | I | T | glioma | (105) |
are promising small-molecules in that they can be developed to be effective METTL3/METTL14 targeting agents (103, 105).

**Targeting m^6^A Readers**

YTHDF1 targeting can be a viable option for cancer therapy, as its elevation promotes cancer growth in different cancers, including GC (85), ovarian cancer (106, 107), CRC (108), and HCC (109). There are different pathways by which YTHDF1 escalates tumor aggressiveness, one of which is through influencing DCs to be less efficient in presenting tumor antigens to T cells. As a result, implementing small molecules or DC vaccines that can suppress YTHDF1 would enhance immunotherapy against cancers (12).

**Targeting m^6^A Erasers**

FTO inhibitors can be effective in sensitizing melanoma tumor tissues to anti-PD-1 blockade immunotherapy and at the same time in promoting IFN-γ induced killing, which is also essential for the ICB response (110, 111). In addition, anti-PD-1 immunotherapy effective at the beginning (112), does not have long-lasting effects (110) due to FTO mediated resistance. Therefore, the combination uses of ICB and FTO inhibitors will likely block this resistance in a host with an adaptive immunity presence. m^6^Am^6^AA recent study has also demonstrated that FTO knockdown sensitizes tumors to anti-PD-1 immunotherapy, except that this sensitization effect is not as robust when compared to ALKBH5 depletion (82). Examples of promising FTO inhibitors include the non-steroidal, anti-inflammatory drug, meclofenamic acid (MA), which is a selective FTO inhibitor (95), the ethyl ester form of meclofenamic acid (MA2) (113–115), and FB23-2 (99). In addition, R-2-hydroxylglutarate (R-2HG), an oncometabolite produced by the isocitrate dehydrogenase (IDH) mutations, inhibit FTO activity, leading to the increase of m6A abundance and decreased stability of MYC and CEBPA mRNAs, which subsequently caused growth inhibition, cell cycle arrest and apoptosis of leukemia cells (116).

ALKBH5 has been shown to be responsible for tumor proliferation in different cancers, including breast cancer (117), glioblastoma (118) and LADC (119), so its inhibition can yield good clinical outcomes if implemented. ALKBH5 knockdown has been shown to sensitize melanoma and colon cancer to overcome the resistance for immunotherapy through downregulating prominent cells (Tregs and MDSCs), which immunosuppresses the anti-tumor immunity, while at the same time upregulating DCs (82). One promising ALKBH5 targeting agent is the imidazobenzoxazin-5-thione MV1035 that shows an ALKBH5 inhibition and repression of GBM cell lines (U87-MG cells) through downregulating CD73 expression (101).

**m^6^A-Targeting With ICB**

Though ICB (such as anti-PD-1/PD-L1 treatment) have achieved significant clinical benefits in cancer patients receiving ICB, the immunotherapeutic outcomes exhibited individual heterogeneity. Thus, there are two problems that needs to be solved: (1) finding markers to predict the outcomes of immunotherapy; (2) figure out strategy to improve efficacy. Different m^6^A signatures model has been proposed to predict the response of anti-PD-1 immunotherapy (See section “m^6^A is associated with TME and immunotherapy efficacy”). Moreover, m^6^A-targeting treatment synchronizing with anti-PD-1 therapy have already shown improved outcome in preclinical studies (Figure 4).

Inhibition of m^6^A mRNA modification by depletion of methyltransferases, Mettl3 and Mettl14, enhanced response to anti-PD-1 treatment in pMMR-MSI-L CRC and melanoma. Mechanistically, Mettl3 or Mettl14 deficiency promoted IFN-γ-Stat1-Ifi1 signaling through stabilizing the Stat1 and Ifi1 mRNA via YTHDF2 (13). However, both FTO and ALKBH5 in tumor cells are proved to decrease response to anti-PD-1 blockade immunotherapy. Knockdown of FTO sensitizes melanoma cells to interferon gamma (IFNγ) and sensitizes melanoma to anti-PD-1 treatment in mice (125). Tumor-intrinsic ALKBH5 inhibited the expansion and cytotoxicity of T cells by sustaining tumor cell PD-L1 expression, which was further confirmed in human intrapheatal cholangiocarcinoma (ICC) specimens (83). Importantly, a small-molecule ALKBH5 inhibitor enhanced the efficacy of cancer immunotherapy in melanoma (82), suggesting that the combination of FTO/ALKBH5 inhibition with anti-PD-1 blockade may reduce the resistance to immunotherapy in melanoma.

Intriguingly, both “writers” inhibition (METTL3 or METTL14) and “erasers” inhibition (FTO or ALKBH5) are proved to enhance the efficacy of anti-PD-1 blockade even in the same cancer (melanoma). It seem contradictory that both of the strategies work, since “writers” and “erasers” are believed to regulate m^6^A modification inversely. The possible explanations for this should include: (1) different targeted mRNA or ncRNA; (2) other potential pathway of “writers” and “erasers”; (3) differences in animal models (gene knockout vs. small molecular inhibitor). In addition, there is insufficient studies regarding the selectivity of target mRNA/ncRNA by “writers”, “readers” and “erasers”, which may explain the question mentioned above. As it is believed that these regulators function by affecting the translation and
degradation of specific mRNA/ncRNA, it is reasonable that both “writers” and “erasers” inhibition can synchronize with anti-PD-1 immunotherapy if they act on different targets. However, future researches are needed to verify the hypothesis.

CONCLUSIONS

In this review, we have highlighted the roles of the different players involved in m6A modifications, their links to the TME and their potential therapeutic implementation against cancers when they are targeted, and we have particularly emphasized their actions as adjuncts to the various forms of immunotherapy. Most of these therapeutic strategies are still in the preclinical stages and haven’t entered clinical use yet. Nonetheless, these strategies show a promising outlook in impairing cancer progression, especially when bypassing the resistance to immunotherapies (e.g., primary, adaptive, or acquired resistances) through mechanisms such as reversing the immunosuppressive TME by increasing the influx of effector cells. As a consequence, these novel potential targets will be a necessary future component to combine with immunotherapy regimens, when subsequent studies further confirm their efficacy.

AUTHOR CONTRIBUTIONS

CQ and OB are major contributors in writing the manuscript. JC and XZ provided guidance throughout the preparation of this manuscript. PL, ZY, and DQ. WR collected and prepared the related papers. JH, HL, AZ, HM, GG, ZQ, MC, and YS reviewed and gave significant advice. All authors contributed to the article and approved the submitted version.

FUNDING

This work was supported by the National Natural Science Foundation of China (81873626, 81902592, 82070785), Hunan Natural Science Foundation (2020JJ5884), Hunan Province Key R&D Program (2019SK2202) and Xiangya Hospital Youth Fund (2018Q09).

REFERENCES

1. Jonkhout N, Tran J, Smith MA, Schonrock N, Mattick JS, Novoa EM. The RNA Modification Landscape in Human Disease. RNA (2017) 23(12):1754–69. doi: 10.1261/rna.063503.117

2. Li S, Mason CE. The Pivotal Regulatory Landscape of RNA Modifications. Annu Rev Genomics Hum Genet (2014) 15:127–50. doi: 10.1146/annurev-genom-090413-025405

3. Boccaletto P, Machnicka MA, Purta E, Pietkowski P, Baginski B, Wreczki TK, et al. MODOMICS: A Database of RNA Modification Pathways. 2017
Quan et al. N6-Methyladenosine in Cancer Immunotherapy

Update. *Nucleic Acids Res* (2018) 46(D1):D303–D7. doi: 10.1093/nar/gkx1030

4. Cancer-Ing R, Fridriek K, Rottman F. Identification of Methylated Nucleosides in Messenger RNA From Novikoff Hepatoma Cells. *Proc Natl Acad Sci USA* (1974) 71(10):3971–5. doi: 10.1073/pnas.71.10.3971

Perry RP, Kelley DE. Existence of Methylated Messenger RNA in Mouse I. Cells. *Cell* (1974) 1(1):37–42. doi: 10.1016/0026-0495(74)90153-6

Huang H, Weng H, Chen J. M(6)A Modification in Coding and Non-Coding RNAs: Roles and Therapeutic Implications in Cancer. *Cancer Cell* (2020) 37(3):270–88. doi: 10.1016/j.ccell.2020.02.004

He Y, Hu H, Wang Y, Yuan H, Lu Z, Wu P, et al. ALKBH5 Inhibits Pancreatic Cancer Motility by Decreasing Long Non-Coding RNA KCNK15–AS1 Methylation. *Cell Physiol Biochem* (2018) 48(2):838–46. doi: 10.1159/000491915

Zhuang C, Zhuang C, Luo X, Huang X, Yao L, Li J, et al. N6-Methyladenosine Demethylase FTO Suppresses Clear Cell Renal Carcinoma Through a Novel FTO-PGC-1α Signalling Axis. *J Cell Mol Med* (2019) 23(3):2163–73. doi: 10.1111/jcmm.14128

Yang F, Jin H, Que B, Chao Y, Zhang H, Ying X, et al. Dynamic M(6)A Methylation Reveals the Role of METTL3–METTL14 in Immune Responses to Anti-PD-1 Therapy. *EMBO J* (2016) 35(12):1742–54. doi: 10.15252/embj.201540514

He Y, Hu H, Wang Y, Yuan H, Lu Z, Wu P, et al. ALKBH5 Inhibits Pancreatic Cancer Motility by Decreasing Long Non-Coding RNA KCNK15–AS1 Methylation. *Cell Physiol Biochem* (2018) 48(2):838–46. doi: 10.1159/000491915

Yue Y, Liu J, Cui X, Cao J, Luo G, Zhang Z, et al. VIRMA Mediates Preferential M(6)A mRNA Methylation in 3’UTR and Near Stop Codon and Associates With Alternative Polyadenylation. *Cell Discov* (2018) 4:10. doi: 10.1038/s41421-018-0019-0

Wang YN, Yu CY, Jin HZ. RNA N(6)-Methyladenosine Modifications and the Immune Response. *J Immunol Res* (2020) 2020:6327614. doi: 10.1155/2020/6327614

Xiao W, Adhikari S, Dalal U, Chen YS, Hao YJ, Sun BF, et al. Nuclear M(6)A Reader YTHDC1 Regulates mRNA Splicing. *Mol Cell* (2016) 61(4):507–19. doi: 10.1016/j.molcel.2016.01.012

Asmodiz SD, Ma J, Anderson SJ, Leu NA, Xu Y, Gregory BD, et al. Nuclear M6a Reader YTHDC1 Regulates Alternative Polyadenylation and Splicing During Mouse Oocyte Development. *Plc0 Genet* (2016) 14(5):e1007412. doi: 10.1371/journal.pgen.1007412

Hsu PJ, Zhu Y, Ma H, Guo Y, Shi X, Liu Y, et al. Yhd2 Is an N(6)-Methyladenosine Binding Protein That Regulates Mammalian Spermatogenesis. *Cell Res* (2017) 27(9):1115–27. doi: 10.1038/cr.2017.99

Kretzschmer J, Rao H, Hackert P, Sloan KE, Hobern A, Bohnsack MT. The M(6)A Reader Protein YTHDC2 Interacts With the Small Ribosomal Subunit and the 5’-3’ Exonucllease XRN1. *RNA* (2018) 24(10):1339–50. doi: 10.1261/rna.064238.117

Wojtas MN, Pandey RR, Mendel M, Homolka D, Sachanandam R, Pillai RS. Regulation of M(6)A Transcripts by the 5’–5’ RNA Helicase YTHDC2 Is Essential for a Successful Metiotic Program in the Mammalian Germline. *Mol Cell* (2017) 68(2):374–87.e12. doi: 10.1016/j.molcel.2017.09.021

Paul W, Jaffrey SR. Reading M(6)A in the Transcriptome: M(6)A-Binding Proteins. *Trends Cell Biol* (2018) 28(2):113–27. doi: 10.1016/j.tcb.2017.10.001

Zaccara S, Ries RJ, Jaffrey SR. Reading, Writing and Erasing mRNA Methylation. *Nat Rev Mol Cell Biol* (2019) 20(10):608–24. doi: 10.1038/s41580-019-0168-5

Mauer J, Luo X, Blanajoie A, Jiao X, Grozhik AV, Patil DP, et al. Reversible Methylolation of M(6)A in the 5’ Cap Controls mRNA Stability. *Nature* (2017) 541(7637):319–23. doi: 10.1038/nature21022

Zheng G, Dahl JA, Niu Y, Fedorcsak P, Huang CM, Li CJ, et al. ALKBH5 Is a Mammalian RNA Demethylase That Impacts RNA Metabolism and Mouse Fertility. *Mol Cell* (2013) 49(1):18–29. doi: 10.1016/j.molcel.2012.10.015

Liu X, Liu J, Xiao W, Zeng Q, Bo H, Zhu Y, et al. SRRTI Regulates N(6)-Methyladenosine RNA Modification in Hepatocarcinogenesis by Inducing RANBP2-Dependent FTO SUMoylation. *Hepatology* (2020) 72(6):2029–50. doi: 10.1002/hep.31222

Alarcn CR, Goodarzi H, Lee H, Liu X, Tavaoie S, Tavaoie SF. HNRNPAP2B1 Is a Mediator of M(6)A-Dependent Nuclear RNA Processing Events. *Cell* (2015) 162(6):299–308. doi: 10.1016/j.cell.2015.08.011

Liu N, Dai Q, Zheng G, He C, Parisien M, Pan T. N(6)-Methyladenosine-Dependent RNA Structural Changes Regulate RNA-Protein Interactions. *Mol Cell* (2015) 58(7):560–4. doi: 10.1016/j.molcel.2014.12.031

Liu N, Zhou KI, Parisien M, Dai Q, Diatchenko L, Pan T. N(6)-Methyladenosine Alters RNA Structure to Regulate Binding of a Low Complexity Protein. *Nucleic Acids Res* (2017) 45(10):6051–63. doi: 10.1093/nar/gkx141

Zhou KI, Shi H, Lyu R, Wylder AC, Matuszek Z, Pan JN, et al. Regulation of Co-Transcriptional Pre-mRNA Splicing by M(6)A Through the Low Complexity Protein hnRNP G. *Mol Cell* (2017) 67(1):70–81.e9. doi: 10.1016/j.molcel.2017.07.005

Marek B, Covelov MH, Pavlina G, Dominika H, Grzegorz K, Stepanka V, N(6)-Methyladenosine Demethylase FTO Targets pre-mRNAs and Regulates Alternative Splicing and 3’-End Processing. *Nucleic Acids Res* (2017) 45(1):11356–11366. doi: 10.1093/nar/gkx141

Lebrel S, Vipakone N, Parker M, Parker J, Heath C, Sudbery I, et al. The M(6)A Methylation Complex Recruitment TREX andRegulates mRNA Export. *Next RNA* (2018) 8(1):13827. doi: 10.1016/j.molcel.2018.03.018

Wang X, Lu Z, Gomez A, Hon GC, Yue Y, Han D, et al. N(6)-Methyladenosine-Dependent Regulation of Messenger RNA Stability. *Nature* (2014) 505(7481):117–20. doi: 10.1038/nature12730

Geula S, Moshtishch-Moshkovitz S, Dominissi D, Mansoor AA, Kol N, Salmon-Divon M, et al. Stem Cells. M6a mRNA Methylation Facilitates
Quan et al. N6-Methyladenosine in Cancer Immunotherapy

Resolution of Naive Pluripotency Toward Differentiation. Science (2015) 347 (6225):1002–6. doi: 10.1126/science.1261417

Ke S, Pandya-Jones A, Saito Y, Fak J, Vagbo CB, Geula S, et al. M(6)A mRNA Modifications are Deposited in Nascent pre-mRNA and Are Not Required for Splicing But do Specify Cytoplasmic Turnover. Genes Dev (2017) 31(10):990–1006. doi: 10.1101/gad.301036.117

Wang X, Zhao BS, Roundtree IA, Lu Z, Han D, Ma H, et al. N(6)-Methyladenosine Modulates Messenger RNA Translation Efficiency. Cell (2015) 161(6):1388–99. doi: 10.1016/j.cell.2015.05.014

Choe J, Lin S, Zhang W, Qin X, Shi H, Wu H, et al. mRNA Circularization by METTL3-Eif3h Enables Translation and Promotes Oncogenesis. Nature (2018) 561(7724):556–60. doi: 10.1038/s41586-018-0123-2

Du H, Zhao Y, He J, Zhang Y, Xi H, Liu M, et al. YTHDF2 Destabilizes M(6)A C-Containing RNA Through Direct Recruitment of the CCR4-NOT Deadenylase Complex. Nat Commun (2017) 7:12626. doi: 10.1038/ncomms12626

Li A, Chen YS, Ping XL, Yang X, Xiao W, Yang Y, et al. Cytoplasmic M(6)A RNA Modifications in Cancer: Novel Therapeutic Opportunities. Mol Cancer (2020) 19(1):121. doi: 10.1186/s12943-020-01233-2

Lee H, Bao S, Qian Y, Geula S, Leslie J, Zhang C, et al. Stage-Specific mRNA M(6)A and Methyladenosine-Modulated Messenger RNA Translation Efficiency. Cell (2015) 161(6):1388–99. doi: 10.1016/j.cell.2015.05.014

Choe J, Lin S, Zhang W, Li Q, Wang L, Ramirez-Moya J, et al. mRNA Circularization by METTL3-Eif3h Enables Translation and Promotes Oncogenesis. Nature (2018) 561(7724):556–60. doi: 10.1038/s41586-018-0123-2

Du H, Zhao Y, He J, Zhang Y, Xi H, Liu M, et al. YTHDF2 Destabilizes M(6)A C-Containing RNA Through Direct Recruitment of the CCR4-NOT Deadenylase Complex. Nat Commun (2017) 7:12626. doi: 10.1038/ncomms12626

Li A, Chen YS, Ping XL, Yang X, Xiao W, Yang Y, et al. Cytoplasmic M(6)A RNA Modification Pattern and Immune Infiltration Characterization in Gastric Cancer. Mol Cancer (2020) 19(1):53. doi: 10.1186/s12943-020-01170-0

Cheng W, Wang L, Liu J, Fang Z, Du F, Wu H, et al. M(6)A Regulator-Based Methylation Modification Patterns Characterized by Distinct Tumor Microenvironment Immune Profiles in Colon Cancer. Theranostics (2021) 11(5):2201–17. doi: 10.7150/thno.52717

Harlin H, Meng Y, Peterson AC, Zha Y, Tretiakov M, Slingsluff C, et al. Chemokine Expression in Melanoma Metastases Associated With CD8+ T-Cell Recruitment. Cancer Res (2009) 69(7):3077–85. doi: 10.1158/0008-5472.can-08-2281

Luu J, Joo B, Reis SF, Spranger S, Gajeiwski TF. WNT/B-Catenin Pathway Activation Correlates With Immune Exclusion Across. Hum Cancers (2018) 19(10):2907–83. doi: 10.1016/j.ctrand.2018.03.019

Zhong J, Liu Z, Cai C, Duan X, Deng T, Zeng G. M(6)A Modification Patterns and Tumor Immune Landscape in Clear Cell Renal Carcinoma. J Immunother Cancer (2021) 9(2):e001646. doi: 10.1136/jitc-2020-001646

Wu X, Sheng H, Wang L, Xia P, Wang Y, Yu L, et al. A Five-M6a Regulatory Gene Signature Is a Prognostic Biomarker in Lung Adenocarcinoma Patients. Aging (Albany NY) (2021) 13(7):10034–57. doi: 10.18632/aging.202761

Li Y, Gu J, Xu F, Zhu Q, Chen Y, Ge D, et al. Molecular Characterization, Biological Function, Tumor Microenvironment Association and Clinical Significance of M6a Regulators in Lung Adenocarcinoma. Brief Bioinform (2019) 20(5):2248–62. doi: 10.1093/bib/bbz050

Mo P, Xie S, Cai W, Ruan J, Du Q, Ye J, et al. N(6)-Methyladenosine (M(6)A) RNA Methylation Signature as a Predictor of Stomach Adenocarcinoma Outcomes and Its Association With Immune Checkpoint Molecules. J Int Med Res (2020) 48(9):200006520951405. doi: 10.1177/0300060520951405

Guo W, Tan F, Huai Q, Wang Z, Shao F, Zhang G, et al. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and M6a RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma. Front Immunol (2021) 12:669750. doi: 10.3389/fimmu.2021.669750

Zhao H, Xu Y, Xie Y, Zhang L, Gao M, Li S, et al. M6a Regulators Is Differently Expressed and Correlated With Immune Response of Esophageal Cancer. Front Cell Dev Biol (2021) 9:590023. doi: 10.3389/fcell.2021.590023

Jiang H, Ning G, Wang Y, Lv W. Identification of an M6a-Related Signature as a Biomarker for Hepatocellular Carcinoma Prognosis and Correlates With Sorafenib and Anti-PD-1 Immunotherapy Treatment Response. Dis Markers (2021) 2021:5576683. doi: 10.1155/2021/5576683

Li J, Wang W, Zhou Y, Liu L, Zhang G, Guan K, et al. M6a Regulator-Associated Modification Patterns and Immune Infiltration of the Tumor Microenvironment in Hepatocarcinoma. Front Cell Dev Biol (2021) 9:687756. doi: 10.3389/fcell.2021.687756

Kessenbrock K, Plaks V, Werb Z. Matrix Metalloproteinases: Regulators of the Tumor Microenvironment. Cell (2010) 141(1):52–67. doi: 10.1016/j.cell.2010.03.015

Zhang Z, Zhou D, Lai Y, Liu Y, Tao X, Wang Q, et al. Estrogen Induces Endometrial Cancer Cell Proliferation and Invasion by Regulating the Fat
Quan et al. N6-Methyladenosine in Cancer Immunotherapy

87. Wang H, Hu X, Huang M, Liu J, Gu Y, Ma L, et al. Mettl3-Mediated mRNA

86. Shang L, Wan Y, Zhang Z, Jiang Y, Lang J, Cheng W, et al. FTO Demethylates

85. Pi J, Wang W, Ji M, Wang X, Wei X, Jin J, et al. YTHDF1 Promotes Gastric

84. Fukumoto T, Zhu H, Nacarelli T, Karakashev S, Fatkhutdinov N, Wu S, et al.

90. Dong L, Chen C, Zhang Y, Guo P, Wang Z, Li J, et al. The Loss of RNA N(6)-

91. Zhou J, Zhang X, Hu J, Qu R, Yu Z, Xu H, et al. M(6)A Demethylase

99. Huang Y, Su R, Sheng Y, Dong L, Dong Z, Xu H, et al. Small-Molecule

94. Aik W, Demetriades M, Hamdan MK, Bagg EA, Yeoh KK, Lejeune C, et al.

98. Qiao Y, Zhou B, Zhang M, Liu W, Han Z, Song C, et al. A Novel Inhibitor of

97. He W, Zhou B, Liu W, Zhang M, Shen Z, Han Z, et al. Identification of A

96. doi: 10.1038/s41467-019-09903-6

95. doi: 10.1016/j.ccell.2019.03.006

91. doi: 10.1016/j.ccell.2019.04.016

90. doi: 10.1038/s41467-018-01095-6

89. doi: 10.1038/ncomms13045

88. doi: 10.1038/s41467-020-00951-w

87. doi: 10.1056/NEJMoa1200694

86. doi: 10.1158/0008-5472.Can-20-0066

85. doi: 10.1093/nar/gkaa048

84. doi: 10.1026/10.1038/sciadv.abg0470

83. doi: 10.1026/10.1038/nature23450

82. doi: 10.1158/0008-5472.Can-2019-04688

81. doi: 10.1038/nat.2019.04687

80. doi: 10.1158/0008-5472.Can-2013-21514-8

79. doi: 10.1158/0008-5472.Can-2012-366(26):2455–65. doi: 10.1016/j.bbamcr.2011.12.033

78. doi: 10.1158/0008-5472.Can-2012-5472

77. doi: 10.1158/0008-5472.Can-2012-58. doi: 10.1158/0008-5472.Can-2010-2014682

76. doi: 10.1158/0008-5472.Can-2012-317(4):738–42. doi: 10.1038/nature23450

75. doi: 10.1152/acs.jmedchem.2001.12.2019

74. doi: 10.1026/10.1093/nar/gkaa048%

73. doi: 10.1038/s41467-018-0139-7

72. doi: 10.1038/nature23450

71. doi: 10.1038/s41618-019-0126-0

70. doi: 10.1158/0008-5472.Can-2013-57(5):590

69. doi: 10.1038/nature23450

68. doi: 10.1093/nar/gku1276

67. doi: 10.1038/s41467-019-11261-9

66. doi: 10.1038/s41467-020-10563-0

65. doi: 10.1016/j.ijcancer.2020.01.017

64. doi: 10.1038/s41467-019-09796-9

63. doi: 10.1038/nature23450

62. doi: 10.1038/nature23450

61. doi: 10.1038/s41467-018-04187-8

60. doi: 10.1158/0008-5472.Can-2012-317(4):738–42. doi: 10.1038/nature23450

59. doi: 10.1158/0008-5472.Can-2012-317(4):738–42. doi: 10.1038/nature23450

58. doi: 10.1056/NEJMoa1200694

57. doi: 10.1158/0008-5472.Can-2012-317(4):738–42. doi: 10.1038/nature23450

56. doi: 10.1152/jcb.2010.373327

55. doi: 10.1038/nature23450

54. doi: 10.1038/nature23450

53. doi: 10.1038/nature23450

52. doi: 10.1038/nature23450

51. doi: 10.1038/nature23450

50. doi: 10.1038/nature23450

49. doi: 10.1038/nature23450

48. doi: 10.1038/nature23450

47. doi: 10.1038/nature23450

46. doi: 10.1038/nature23450

45. doi: 10.1038/nature23450

44. doi: 10.1038/nature23450

43. doi: 10.1038/nature23450

42. doi: 10.1038/nature23450

41. doi: 10.1038/nature23450

40. doi: 10.1038/nature23450

39. doi: 10.1038/nature23450

38. doi: 10.1038/nature23450

37. doi: 10.1038/nature23450

36. doi: 10.1038/nature23450

35. doi: 10.1038/nature23450

34. doi: 10.1038/nature23450

33. doi: 10.1038/nature23450

32. doi: 10.1038/nature23450

31. doi: 10.1038/nature23450

30. doi: 10.1038/nature23450

29. doi: 10.1038/nature23450

28. doi: 10.1038/nature23450

27. doi: 10.1038/nature23450

26. doi: 10.1038/nature23450

25. doi: 10.1038/nature23450

24. doi: 10.1038/nature23450

23. doi: 10.1038/nature23450

22. doi: 10.1038/nature23450

21. doi: 10.1038/nature23450

20. doi: 10.1038/nature23450

19. doi: 10.1038/nature23450

18. doi: 10.1038/nature23450

17. doi: 10.1038/nature23450

16. doi: 10.1038/nature23450

15. doi: 10.1038/nature23450

14. doi: 10.1038/nature23450

13. doi: 10.1038/nature23450

12. doi: 10.1038/nature23450

11. doi: 10.1038/nature23450

10. doi: 10.1038/nature23450

9. doi: 10.1038/nature23450

8. doi: 10.1038/nature23450

7. doi: 10.1038/nature23450

6. doi: 10.1038/nature23450

5. doi: 10.1038/nature23450

4. doi: 10.1038/nature23450

3. doi: 10.1038/nature23450

2. doi: 10.1038/nature23450

1. doi: 10.1038/nature23450

1. doi: 10.1038/nature23450
119. Chao Y, Shang J, Ji W. ALKBH5-M(6)A-FOXM1 Signaling Axis Promotes Proliferation and Invasion of Lung Adenocarcinoma Cells Under Intermittent Hypoxia. *Biochem Biophys Res Commun* (2020) 521(2):499–506. doi: 10.1016/j.bbrc.2019.10.145

120. Spangler S, Bao R, Gajewski TF. Melanoma-Intrinsic β-Catenin Signalling Prevents Anti-Tumour Immunity. *Nature* (2015) 523(7559):231–5. doi: 10.1038/nature14404

121. Ganesh S, Shui X, Craig KP, Park J, Wang W, Brown BD, et al. RNAi-Mediated β-Catenin Inhibition Promotes T Cell Infiltration and Antitumor Activity in Combination With Immune Checkpoint Blockade. *Mol Ther* (2018) 26(11):2567–79. doi: 10.1016/j.ymthe.2018.09.005

122. Liang X, Fu C, Cui W, Ober-Blöbaum JL, Zahner SP, Shrikant PA, et al. β-Catenin Mediates Tumor-Induced Immunosuppression by Inhibiting Cross-Priming of CD8⁺ T Cells. *J Leukoc Biol* (2014) 95(1):179–90. doi: 10.1189/jlb.0613330

123. Hong Y, Manoharan I, Suryawanshi A, Shanmugam A, Swafford D, Ahmad S, et al. Deletion of LRP5 and LRP6 in Dendritic Cells Enhances Antitumor Immunity. *Oncoimmunology* (2016) 5(4):e1115941. doi: 10.1080/2162402x.2015.1115941

124. Yaguchi T, Goto Y, Kido K, Mochimaru H, Sakurai T, Tsukamoto N, et al. Immune Suppression and Resistance Mediated by Constitutive Activation of Wnt/β-Catenin Signaling in Human Melanoma Cells. *J Immunol* (2012) 189(5):2110–7. doi: 10.4049/jimmunol.1102282

125. Yang S, Wei J, Cui Y-H, Park G, Shah P, Deng Y, et al. M6a mRNA Demethylase FTO Regulates Melanoma Tumorigenicity and Response to Anti-PD-1 Blockade. *Nat Commun* (2019) 10(1):2782. doi: 10.1038/s41467-019-10669-0

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher's Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.